Key Takeaways for Selling Your Dental Practice in 2026
- Most dental practice sales without professional representation do not close. DIY close rates often sit near 15–20%, while well-run brokered processes can reach about 80%.
- McLerran & Associates often delivers an 85–90% transaction rate by running a structured, competitive auction that typically generates about 10 offers per listing from a vetted buyer pool.
- CPA-led, diligence-grade valuations can protect sellers from post-offer renegotiations and can produce higher realized prices than free or napkin-math valuations.
- Owners in the $1.5 million to $3 million revenue range can benefit from McLerran’s balanced 50/50 private-buyer and DSO process, which allows side-by-side comparisons of after-tax proceeds before committing.
- Ready to see what your practice is worth on both paths? Schedule a free, confidential discovery call with McLerran & Associates today.
Why Many Dental Practice Sales Fall Apart Without the Right Advisor
A dental practice sale is one of the most complex transactions a doctor may ever navigate, and many do not reach the finish line. Roughly 80–85% of dental practices sold without professional representation fall apart before closing. Do-it-yourself close rates can run as low as 15–20%, compared with roughly 80% for a well-run brokered process.
The reasons can be structural. A practice owner sells once in a career, while a DSO negotiates acquisitions every week. The two transition paths, selling to a solo doctor buyer or affiliating with a DSO or private equity partner, involve different math, different structures, and different post-close lives. An owner who enters either path without a dedicated sell-side advisor can face a significant information disadvantage.
The four main broker categories each carry distinct risks for sellers:
- DIY / for-sale-by-owner: No competitive tension, no professional valuation, and a close rate that research places at 15–20%. The buyer effectively sets the price.
- Local generalist brokers: Limited market exposure, relationships with only a few DSOs, and weaker underwriting, which can cause buyers to bid less aggressively on their listings over time.
- Multi-vertical advisors: Deal experience across many healthcare verticals, but without the dental-only buyer relationships, specialty nuance, and regional market intelligence that dental-specific focus can provide.
- “Free valuation” firms: A back-of-the-napkin number used as a lead magnet can become the anchor that quietly determines what the owner walks away with. Aggressive EBITDA add-backs that are not properly documented are frequently challenged during diligence, which can reduce credibility and lead to lower realized valuations or failed deals.
Common operational factors can also derail a sale before it begins. Throttling new patient flow, flat revenue trends, and declining digital presence can signal managed decline to buyers regardless of current profitability. Provider concentration, where the owner performs 90% or more of production, can trigger a 10–20% valuation reduction and was one of the top reasons DSOs walked from deals in 2025. These structural challenges help explain why professional representation can matter, and why the mechanism behind that representation often centers on competitive tension.
How Competitive Processes Can Lift Your Practice Valuation
Marketed processes that involve multiple buyers can produce final transaction values above initial unsolicited offers. McLerran & Associates applies this principle through a structured, auction-style bid process that typically runs 45 to 60 days. This process can generate multiple offers per listing from a vetted pool of well-qualified buyers.
The result can be a valuation lift compared with what many owners achieve when selling on their own. Buyers know they are competing, so they often sharpen both price and terms. Owners gain a clearer view of the market rather than relying on a single offer that may not reflect full value.
Comparing DSO and Private Buyers for Your Practice
The right transition path can depend on practice size, profitability, and the owner’s personal “why.” DSO buyers can offer higher headline valuations than individual buyers. These deals are often structured with a portion paid in cash at closing, some as earnouts tied to performance targets, and some as equity rollover that is illiquid and carries platform performance risk. Earnouts are deferred payments tied to revenue or EBITDA targets over a defined post-close period. Rollover equity is a minority ownership stake in the DSO that is realized only when the platform is sold again, typically in 3 to 7 years.
Private doctor-to-doctor sales can deliver most of the purchase price in cash at closing, with moderate complexity and timelines of 4 to 8 months. DSO sales can involve higher complexity across multiple interconnected documents and can take 8 to 18 months. A private sale can offer a cleaner exit and full cash certainty. A DSO affiliation can offer a higher headline and a potential second payout when the platform recapitalizes, but it usually requires a multi-year employment commitment, often 3 to 5 years, and introduces earnout performance risk.
Platform DSOs, portfolio DSOs, dental partnership organizations, and management services organizations can price acquisitions with very different cash mixes, rollover-equity terms, employment commitments, and post-close autonomy structures. Telling them apart can require dental-specific expertise that a generalist advisor may not have.
McLerran & Associates works both paths in roughly equal measure, an approximately 50/50 split that is rare among national advisory firms. This approach produces a genuine side-by-side valuation. Owners in the $1.5 million to $3 million revenue range, who can realistically pursue either path, can compare their worth and projected after-tax proceeds across deal structures and time horizons before committing. Specialty also shapes the analysis. Oral and maxillofacial surgery, orthodontics, and pediatric dentistry can attract strong DSO interest and can command premium valuations, while general dentistry continues to earn aggressive, near-all-time-high valuations in the private-buyer market. McLerran reads these specialty-by-specialty and region-by-region dynamics rather than treating every practice the same.
Schedule a free, confidential discovery call with McLerran & Associates to get a side-by-side comparison of what your practice may be worth on both paths, with no obligation to proceed.
CPA-Led Valuations That Can Survive Buyer Diligence
Valuation is often where most of the quiet damage occurs. A “free” number set by the buyer can become the anchor that determines what the owner walks away with. A weak analysis can be challenged the moment a sophisticated buyer’s quality-of-earnings team examines the books. Quality of earnings is the buyer’s independent review of whether the EBITDA a seller claims is likely to continue after the ownership change.
Sellers who prepare 12 to 24 months in advance, clean up financials, document add-backs properly, and reduce owner dependency can often achieve higher multiples than those who rush to market with messy books and hard-to-verify adjustments. Add-backs are legitimate expenses that inflate the owner’s personal compensation or reflect one-time costs. These are added back to reported profit to show a buyer the recurring earnings of the practice.
McLerran’s CPA-led EBITDA analysis is diligence-grade work completed before the deal goes to market. Every add-back is unpacked and documented. The result is a number that can hold when buyers scrutinize it, and a negotiating position that is less likely to collapse under pressure. When a buyer’s quality-of-earnings team pushes back during due diligence, McLerran defends the EBITDA it underwrote and reminds buyers that other vetted bidders remain in the process.
Beyond the headline number, McLerran models what each path may net the owner over time. The firm forecasts private-buyer and DSO outcomes across major deal structures over 3-, 5-, 7-, and 10-year horizons, including conservative recapitalization assumptions. Differences in purchase-price allocation between goodwill, equipment recapture, consulting agreements, and non-competes can create substantial variations in after-tax proceeds. Structure can matter as much as the multiple.
McLerran also negotiates all aspects of the letter of intent, the binding term sheet that locks in deal structure before full due diligence begins. The team pushes for non-punitive earnout provisions, favorable equity terms, and cash-at-close percentages that reflect the owner’s priorities. Once terms are locked, the firm quarterbacks the close, assembles the right advisor network, and serves as the buffer between parties through every twist of the transaction. This approach helps the deal structure negotiated in the letter of intent survive through closing.
The numbers behind this approach include approximately 2,000 successful practice sales, roughly $2 billion in closed transaction volume, more than 10,000 practices evaluated, and a transaction rate of about 85–90%, compared with an industry norm closer to 35–40%. McLerran does not simply list practices. It focuses on getting them sold.
Not sure whether now is the right time? McLerran can update your valuation for free a year later rather than push you into a deal that is not ready. Get started with a discovery call, or join the McLerran M&A Summit on October 29–30, 2026, earn 4 CE credits, and receive a complimentary $2,500 practice valuation with no obligation to sell.
Frequently Asked Questions
Should I sell to a DSO or a private buyer?
The right path can depend on your practice’s size, profitability, and what you want your life to look like after the transaction. Smaller premier practices, roughly $1 million to $1.5 million in annual revenue, often fit a doctor-to-doctor sale that can deliver a clean exit, full cash at closing, and a short transition period. Larger practices, particularly those above $1.5 million in revenue, are more likely to attract DSO or private equity interest, which can offer a higher headline valuation but typically require a 3- to 5-year post-sale employment commitment and include a portion of the deal in rollover equity and earnouts rather than cash. As discussed earlier, many mid-sized practices can realistically pursue either path, and McLerran’s balanced work across both markets can support a genuine side-by-side comparison of projected after-tax proceeds before you decide.
Why should I pay for a valuation when other firms offer one for free?
A free valuation often functions as a lead-generation tool, a back-of-the-napkin number that has not been stress-tested against the scrutiny a sophisticated buyer will apply. When a buyer’s quality-of-earnings team examines your financials during due diligence, an undocumented or inflated add-back can unravel the agreed price and trigger a renegotiation or end the deal entirely. McLerran’s CPA-led EBITDA analysis is diligence-grade work completed before the deal goes to market, with every add-back unpacked and documented. The number is designed to hold when buyers look closely, which can reduce the risk of the deal being re-traded. In one documented case, a free valuation placed a practice at $2.5 million. McLerran valued it at $4.5 million, and it sold for $5.25 million after a competitive process. The gap between a weak valuation and a defensible one can sometimes be measured in millions.
How do I know which DSOs are the good ones?
Vetting buyers is a core part of McLerran’s mandate. Among the many DSOs active in the market, including large national platforms, mid-market regional groups, and newer entrants that emerged when capital flowed into the space after COVID, quality can vary widely. Some offer strong post-close infrastructure, clinical autonomy, and a track record of satisfied sellers. Others may be undercapitalized, poorly managed, or known for creating difficult post-close environments.
McLerran has blacklisted DSOs that fall into the latter category, so they never reach the table. For the buyers that do, McLerran helps owners underwrite the DSO like an investment. The team looks at whether the company is profitable, whether revenue is still growing at the offices it already owns, whether the management team is experienced, and whether the private equity firm backing it has successfully exited similar platforms before. Because as much as 40% of a DSO deal can be paid in equity rather than cash, partnering with the wrong buyer can put a large share of your proceeds at risk.
What happens to my staff and patients after I sell?
Protecting staff and patients can be a central part of a successful transition. McLerran focuses on both financial outcome and buyer quality, identifying buyers whose strategy, support model, and operational approach align with what you want for the practice you leave behind. The firm serves as the buffer between seller and buyer throughout the process, which can help protect staff relationships, patient goodwill, and practice momentum.
On a doctor-to-doctor sale, the buyer is a fellow clinician who usually respects the existing clinical culture. On a DSO affiliation, McLerran steers owners toward buyers with a documented track record of preserving staff, maintaining patient care standards, and delivering on the operational support they promise, and away from buyers who do not.
Is 2026 a good time to sell a premier dental practice?
Demand for premier, Class A dental practices remains strong, and valuations for well-prepared practices sit near all-time highs. The DSO consolidation wave continues. Approximately 200 DSO affiliations occurred annually in 2024–2025 based on reported transactions, and institutional capital remains committed to the space.
At the same time, the market has become more selective since the 2021–2022 peak. Buyers are conducting more careful diligence, earnout components have grown, and practices with weak financials, high owner dependence, or staffing instability can face compressed offers. Owners who achieve some of the strongest outcomes in 2026 are likely to be those who arrive at market with clean, documented financials, a diligence-grade valuation, and a competitive process behind them. McLerran can provide an honest assessment of where your specific practice stands, and if you are not ready, the firm can update your valuation for free a year later rather than push you into a deal before the time feels right.
